KRAS and neoplasm: Interestingly, when both tumour origin and HPV status were taken into account, the rate of KRAS mutations was significantly lower in anal gland/transitional-type neoplasms (8/24, 33.3%) (especially in HPV-positive tumours (2/10, 20%)) compared to their colorectal-type counterparts (24/44, 54.5%) (Fig. 4d, e).